目的：探讨艾司西酞普兰与帕罗西汀治疗精神分裂症后抑郁障碍的临床疗效和安全性。方法将60例精神分裂症后抑郁障碍患者随机分为两组，每组30例，两组均维持原用抗精神病药物治疗，在此基础上研究组口服艾司西酞普兰治疗，对照组口服帕罗西汀治疗，观察4周。于治疗前后采用汉密顿抑郁量表评定抑郁状况，副反应量表评定不良反应。结果治疗第2周末起两组汉密顿抑郁量表评分均较治疗前有显著下降（P ＜0．01），研究组治疗第2周末评分显著低于对照组（P＜0．01），其他时点评分两组比较差异无显著性（P＞0．05）；治疗4周末两组有效率比较差异无显著性（P ＞0．05）。两组不良反应均较轻微，发生率比较差异无显著性（ P ＞0．05）。结论艾司西酞普兰与帕罗西汀均能显著改善精神分裂症后抑郁障碍患者的抑郁症状，总体疗效相当，安全性高，依从性好，但艾司西酞普兰起效更快，有利于提高患者的治疗依从性。%Objective To explore the efficacy and safety of escitalopram and paroxetine in the treatment of post‐schizophrenic depression (PSD) .Methods Sixty PSD patients were randomly assigned to two groups of 30 ones each ,both groups maintained original antipsychotic treatment ,on this basis research group took orally escitalopram and control did paroxetine for 4 weeks .Depressive conditions were assessed with the Hamilton Depression Scale (HAMD) and adverse reactions with the Treatment Emergent Symptom Scale (TESS) before and after treatment .Results Since the end of the 2nd week the HAMD scores of both groups lowered more significantly compared with pretreatment (P< 0 .01) ,that was significantly lower in research than in control group at the end of the 2nd week (P < 0 .01) ,and there were no significant group differences at other time‐points (P> 0 .05) ;there was no significant group difference in effective rate (P>0 .05) .Adverse reactions of both groups were mild ,there were no significant group differences in the inci‐dences of adverse reactions (P > 0 .05) .Conclusion Both escitalopram and paroxetine could improve the depressive symptoms of PSD patients ,their total efficacies are equivalent ,both have higher safety and bet‐ter compliance ,but the former takes effect more rapidly and is beneficial to the improvement of treatment compliance .
展开▼
